TEMPEST THERAPEUTICS INC

TPSTNASDAQ

🏆 #3634 by market capEarnings Nov 3 · PostUS Equity

$863.51▼ $9.76 (−1.13%)

Simulated price

1h—

24h▼ 1.1%

7d▲ 94770.4%

14d▲ 97726.0%

30d▲ 87379.5%

1y▲ 10053.0%

🏦Market Cap

$19M

Small Cap

📈Revenue Growth (YoY)

-6.3%

Declining

📊Gross Margin

-46.7%

Thin

💵FCF Margin

—

⚖️P/S Ratio

55.4x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $858.40 – $870.06
52-Week Range: $0.84 – $12.23
Volume: $2.81B
Avg Volume: $3.53B
Shares Outstanding: 16.0M
Next Earnings: Oct 9, 2026

Fundamentals Snapshot

Annual Revenue: $340,352
Last Q Revenue: $91,947
P/E Ratio: —
P/S Ratio: 55.4x
EPS (TTM): $-6.21
Dividend Yield: —

Why Investors Own TPST

✓High-growth profile — revenue up +4.6% YoY with expanding US Equity exposure.
✓Healthy economics — 43% gross margin and 15% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$340,352▲ +6.7% YoY

Gross Margin (TTM)

42.8%▲ +2.1% YoY

Operating Income (TTM)

$101,765▲ +6.7% YoY

Free Cash Flow (TTM)

$51,393▲ +6.7% YoY

About TEMPEST THERAPEUTICS INC

Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.

🦦